Olema Pharmaceuticals, Inc. Board of Directors

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Dr. Sean P. Bohen M.D., Ph.D.

Dr. Sean P. Bohen M.D., Ph.D.

President, CEO & Director

Mr. Shane William Charles Kovacs M.B.A.

Mr. Shane William Charles Kovacs M.B.A.

Chief Operating & Financial Officer

Dr. David C. Myles Ph.D.

Dr. David C. Myles Ph.D.

Chief Discovery & Non-Clinical Development Officer

Ms. Courtney O'Konek

Ms. Courtney O'Konek

Vice President of Corporate Communications

Ms. Sasha Austin CPA

Ms. Sasha Austin CPA

VP of Finance & Controller

Ms. Julie Dexter

Ms. Julie Dexter

Senior VP & Head of People

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.